Abstract:Dezocine is a partial MOR agonist previously used clinically in the USA and currently in China. It has been proposed that dezocine be reintroduced to clinical use in the USA, as an analgesia and/or an additional tool to treat opioid use disorder. To consider the clinical reintroduction of dezocine knowing its abuse liability is important. In this review, we found no reports of abuse, dependence or overdose in the English literature, and a small number of cases of dependence in the Chinese literature. If it is less or non‐addictive than other opioids, its short half‐life would allow it to bridge to other medication assisted therapies, facilitate tapering of opioid use and perhaps be used as a rescue medication in those trying to reduce opioid use. Aims Opioid use disorder (OUD) remains a serious public health problem. Opioid maintenance treatment is effective but under‐utilized, hard to access under existing federal regulations, and, once patients achieve OUD stability, challenging to discontinue. Fewer than 2% of persons with OUD stop using opioids completely. There have been calls from public advocacy groups, governmental agencies, and public health officials for new treatments for OUD. Dezocine, a non‐scheduled opioid previously used in the United States and currently widely prescribed in China for pain management, could be a candidate for a novel OUD treatment medication in the U.S. Nonetheless, to date, there have been no reviews of the clinical and preclinical literature detailing dezocine's abuse potential, a key consideration in assessing its clinical utility. Discussion There are no English language reports of human abuse, dependence, or overdose of dezocine, despite years of extensive clinical use. There are a few case reports of dezocine abuse in the Chinese literature, but there are no reports of overdose deaths. Dezocine is perceived as an opioid and is "liked" by opioid‐experienced human and non‐human primates, properties that are not dose‐dependent and are mitigated by ceiling effects—higher doses do not result in more "liking." There is little withdrawal, spontaneous or precipitated, in humans, monkeys, rats, or mice treated chronically with dezocine alone. However, at some doses, dezocine can precipitate withdrawal in humans and monkeys dependent on other opioids. In rodents, dezocine reduces the severity of morphine withdrawal and the rewarding properties of other opioids. Conclusions Although dezocine is reinforcing in humans and monkeys with prior or concurrent opioid use within a restricted dose range, there are only a few anecdotal reports of dezocine abuse despite of the long history of use in humans. Given the evidence of dezocine's limited abuse potential, it could be useful both as a treatment for OUD. However, in‐depth studies would be required for dezocine to be re‐considered for clinical use.

The Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review

Opioid Analgesics-Related Pharmacokinetic Drug Interactions: from the Perspectives of Evidence Based on Randomized Controlled Trials and Clinical Risk Management

IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders

Pharmacodynamic effects following co-administration of cannabinoids and opioids: A scoping review of human experimental studies

Navigating new norms: Addiction specialists' perspectives on opioid use disorder treatments and policy challenges in the fentanyl era

Understanding Healthcare Providers' Care for Patients with Medications Treating Opioid Use Disorder in the Emergency Department: A Scoping Review

Synthetic opioids: a review and clinical update

Stimulant use among patients in opioid treatment settings: Provider perspectives

High-Dose Opioid Prescribing in Individuals with Acute Pain: Assessing the Effects of US State Opioid Policies

A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder

Opioid Use Disorder: Treatments and Barriers

Pharmacological treatment of pain among persons with opioid addiction: A systematic review and meta‐analysis with implications for drug development

Trends in hydrocodone combination product exposures reported to California Poison Control System (CPCS) following DEA rescheduling

The Impact of Nonpharmacological Interventions on Opioid Use for Chronic Noncancer Pain: A Scoping Review

Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability

Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder

Implications of opioid-sparing medications in critically ill patients: A scoping review

Examining the effect of prescription drug monitoring program integration and mandatory use policies on the distribution of methadone and buprenorphine for opioid use disorder, United States, 2009-2021

μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges

The Impact of Patient Characteristics and Postoperative Opioid Exposure on Prolonged Postoperative Opioid Use: An Integrative Review

U.S. Healthcare Workers' Perspective of Outpatient Provision of Methadone: A Scoping Review